Contains aspirin and carisoprodolStrong evidence

Is Aspirin and Carisoprodol affected by genetics?

Partially. 1 of 2 ingredients has pharmacogenetic evidence.

Genes CYP2C19

Aspirin and carisoprodol contains 2 active ingredients, and 1 of them has published pharmacogenetic guidelines. The relevant gene is CYP2C19. Your genotype can change how that ingredient behaves in your body, while the other ingredients aren't affected by genetics in any clinically established way. The strongest evidence level on this page is Strong, from the published guidelines shown below.

Pharmacogenetic guidelines are written for one ingredient at a time, so the guidance below is for each ingredient on its own. What your genes mean for a combination product is less clear, because the dose and the other ingredients can change things. If you take Aspirin and carisoprodol, it's worth talking over with your prescriber or pharmacist. How we handle combination products.

What's in Aspirin and carisoprodol

Aspirin No known pharmacogenetics

No strong published pharmacogenetic guideline currently applies to aspirin.

Carisoprodol Affected by CYP2C19

Affected by CYP2C19. Guidance from FDA, strong evidence.

Read the full carisoprodol genetics guide

Considering GeneSight for Aspirin and carisoprodol?

Gene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $50 with the Full Report instead of several hundred, and works with your existing 23andMe data. Already have a GeneSight report? Use your GeneSight results.

See the comparison

Carisoprodol phenotype recommendations

Published guidance from FDA on how carisoprodol should be dosed or substituted based on your CYP2C19 phenotype.

Phenotype	What it means	Recommendation	Evidence
Ultrarapid MetabolizerCYP2C19	Your body processes carisoprodol faster than normal. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	Not rated
Rapid MetabolizerCYP2C19	Your body processes carisoprodol slightly faster than normal. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	Not rated
Normal MetabolizerCYP2C19	Your body processes carisoprodol at a normal rate. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	Strong
Intermediate MetabolizerCYP2C19	Your body breaks down carisoprodol slightly slower than normal. The standard dose should work as expected.	FDA Initiate therapy with recommended starting dose.	Moderate
Poor MetabolizerCYP2C19	Your body breaks down carisoprodol much more slowly than normal, causing the drug to build up to higher levels. Use with caution, as this increases the risk of side effects.	FDA Use with caution.	Strong
Likely Intermediate MetabolizerCYP2C19	Your body likely breaks down this drug more slowly, so more of it builds up. This can raise the risk of side effects.	FDA No specific dosing change in the FDA table. Refer to FDA labeling.	Moderate
Likely Poor MetabolizerCYP2C19	Your body likely breaks down this drug much more slowly, so more of it builds up. This can raise the risk of side effects.	FDA Use with caution.	Strong
IndeterminateCYP2C19	The impact of your genotype on response to this drug is unknown.	FDA Initiate therapy with recommended starting dose.	Not rated
Not availableCYP2C19	The impact of your genotype on response to this drug is unknown.	FDA Initiate therapy with recommended starting dose.	Not rated

Source: FDA

The gene behind the guidance

CYP2C19 Cytochrome P450 2C19

CYP2C19 handles several SSRIs (citalopram, escitalopram, sertraline), proton pump inhibitors (omeprazole, esomeprazole), and the blood thinner clopidogrel. About 2 percent of people of European ancestry and 13 percent of people of East Asian ancestry are poor metabolizers, and about 30 percent of people of European ancestry are rapid or ultrarapid metabolizers.

For most CYP2C19 drugs, such as the SSRIs and proton pump inhibitors, poor metabolizers build up more drug and rapid or ultrarapid metabolizers clear it faster. Clopidogrel works the other way: it needs CYP2C19 to become active, so poor and intermediate metabolizers get less benefit from it.

See all drugs affected by CYP2C19

Browse the full drug class: Pain medications.

Related medications

Find out how your genetics affect Aspirin and carisoprodol

This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.

Get my report Look up another medication

Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.